GAM
NVCR icon

Gemmer Asset Management’s NovoCure NVCR Stock Holding History

Gemmer Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$6K – 1456
2020
Q3 		$6K Hold
50
– – ﹤0.01% 807
2020
Q2 		$3K Buy
+50
New +$3.29K ﹤0.01% 1060

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gemmer Asset Management's NVCR Position: Q4 2020 in Review

Gemmer Asset Management sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 50 shares — an estimated $6K sold.

Gemmer Asset Management first reported a position in NVCR in Q2 2020 and held it in 2 quarters. The position peaked at $6K in Q3 2020. 356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

  • Gemmer Asset Management reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
  • Gemmer Asset Management sold 50 NovoCure shares in Q4 2020, an estimated $6K.
  • Gemmer Asset Management first reported a position in NovoCure in Q2 2020 and held it in 2 quarters.
  • Gemmer Asset Management's NovoCure position peaked at $6K in Q3 2020.
  • 356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Gemmer Asset Management's 13F filing for Q4 2020, filed 28 Jan 2021.